| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CACNG5 |
| Uniprot No | Q9UF02 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-296aa |
| 氨基酸序列 | MSACGRKALTLLSSVFAVCGLGLLGIAVSTDYWLYLEEGVIVPQNQSTEIKMSLHSGLWRVCFLAGEERGRCFTIEYVMPMNTQLTSESTVNVLKMIRSATPFPLVSLFFMFIGFILNNIGHIRPHRTILAFVSGIFFILSGLSLVVGLVLYISSINDEMLNRTKDAETYFNYKYGWSFAFAAISFLLTEVKPVTLSMDRLGLGTAPLSRGEWGWGRRDIPQPFWTPDHPLYFPSSSQNVSLSYLSGSPPARMSPGPCSCPHVHFPPHSSCVLCRPQPREMRQAPAASPSSAVFSL |
| 分子量 | 59.2 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人CACNG5蛋白的3条参考文献示例(内容基于常见研究方向虚构，建议通过学术数据库验证具体文献)：
---
1. **文献名称**: *"CACNG5 modulates voltage-gated calcium channel trafficking and synaptic transmission in hippocampal neurons"*
**作者**: Smith J, et al. (2005)
**摘要**: 研究揭示了CACNG5作为钙通道γ亚基家族成员，在调控神经元电压门控钙通道(VGCC)的膜运输和稳定性中的作用。通过重组人CACNG5蛋白的体外表达实验，发现其过表达显著增强钙电流密度，并参与海马神经元突触传递的调节。
---
2. **文献名称**: *"Structural insights into the interaction of CACNG5 with Cav1.2 calcium channels"*
**作者**: Wang X, et al. (2018)
**摘要**: 该研究通过冷冻电镜解析了重组人CACNG5蛋白与Cav1.2通道α1亚基的复合物结构，揭示了CACNG5的跨膜结构域与通道孔形成区域的结合位点，为理解γ亚基调控通道门控动力学的分子机制提供了结构基础。
---
3. **文献名称**: *"CACNG5 mutations alter calcium channel function and contribute to seizure susceptibility"*
**作者**: Lee S, et al. (2010)
**摘要**: 通过构建携带CACNG5点突变的HEK293细胞模型，发现重组人CACNG5蛋白的某些突变体(如R187Q)可异常增强钙通道失活速率，导致神经元兴奋性升高，提示CACNG5基因变异可能作为癫痫等疾病的潜在遗传因素。
---
4. **文献名称**: *"CACNG5 overexpression in breast cancer correlates with chemoresistance via calcium signaling pathways"*
**作者**: Brown K, et al. (2021)
**摘要**: 研究利用重组CACNG5蛋白及基因沉默技术，证明其在乳腺癌细胞中通过增强胞内钙振荡激活PI3K/AKT通路，从而促进化疗药物耐药性，为靶向CACNG5的癌症治疗策略提供了依据。
---
**提示**：以上为模拟示例，实际文献需通过PubMed或Google Scholar检索关键词“CACNG5”、“recombinant human CACNG5”、“voltage-gated calcium channel”等获取。
The recombinant human CACNG5 protein is derived from the CACNG5 gene, which encodes a member of the voltage-gated calcium channel gamma subunit family. These proteins, part of the transmembrane AMPA receptor regulatory protein (TARP) subfamily, modulate the trafficking and gating of calcium channels and AMPA receptors, influencing neuronal excitability and synaptic plasticity. CACNG5. also termed gamma-5. is primarily expressed in the central nervous system and interacts with calcium channel α1 subunits or AMPA receptors to regulate ion flux and receptor localization. Structurally, it contains four transmembrane domains and cytoplasmic N- and C-termini, typical of TARP proteins. While its specific physiological roles are less characterized compared to other TARPs (e.g., CACNG2/Stargazin), studies suggest potential involvement in neurological disorders, including epilepsy and neuropsychiatric conditions. Recombinant CACNG5 is produced in heterologous expression systems (e.g., E. coli, HEK293 cells) for functional studies, enabling exploration of its interactions with ion channels, receptor modulation mechanisms, and pathological implications. Its applications span structural biology, drug screening for channelopathies, and deciphering synaptic transmission pathways. However, detailed molecular mechanisms and disease associations of CACNG5 remain understudied, necessitating further research to clarify its contributions to neural circuitry and therapeutic potential.
×
